LYPQOZET Drug Patent Profile
✉ Email this page to a colleague
When do Lypqozet patents expire, and when can generic versions of Lypqozet launch?
Lypqozet is a drug marketed by Althera Pharms and is included in one NDA.
The generic ingredient in LYPQOZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LYPQOZET?
- What are the global sales for LYPQOZET?
- What is Average Wholesale Price for LYPQOZET?
Summary for LYPQOZET
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
DailyMed Link: | LYPQOZET at DailyMed |
Pharmacology for LYPQOZET
Drug Class | Dietary Cholesterol Absorption Inhibitor HMG-CoA Reductase Inhibitor |
Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Physiological Effect | Decreased Cholesterol Absorption |
US Patents and Regulatory Information for LYPQOZET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Althera Pharms | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-001 | Apr 26, 2017 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Althera Pharms | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-004 | Apr 26, 2017 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Althera Pharms | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-002 | Apr 26, 2017 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Althera Pharms | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-003 | Apr 26, 2017 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |